drugset
drugset / Trial / NCT06947850

DOMPE -MT Neurotrophic Keratitis

NCT06947850 ↗

Phase 4 Active not recruiting 10 enrolled Toyos Clinic
RandomizedParallel-groupOpen-labelTreatment

Summary

TITLE: Toyos Clinic / A Phase 4 Study to Assess Longer Duration of Treatment with Cenegermin in Moderate to Severe Dry Eye-Associated Neurotrophic Keratitis

Timeline

Start
2023-01-21
Primary completion
2025-09-25
Completion
2025-09-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cenegermin Protein / enzyme biologic 20 ug/ml Topical

Indications

dry eye syndrome neurotrophic keratoconjunctivitis